Mark A. Currier
YOU?
Author Swipe
View article: Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma Open
We previously reported that the DNA alkylator and transcriptional-blocking chemotherapeutic agent trabectedin enhances oncolytic herpes simplex viroimmunotherapy in human sarcoma xenograft models, though the mechanism remained to be elucid…
View article: Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy Open
Background Pediatric patients with recurrent/metastatic Ewing sarcoma (ES) have a dismal 5-year survival. Novel therapeutic approaches are desperately needed. Natural killer (NK) cell number and function are low in ES patient tumors, in la…
View article: Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors Open
[This corrects the article DOI: 10.3389/fimmu.2024.1384623.].
View article: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors Open
Introduction Malignant peripheral nerve sheath tumors (MPNST) pose a significant therapeutic challenge due to high recurrence rates after surgical resection and a largely ineffective response to traditional chemotherapy. An alternative tre…
View article: Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma Open
We previously reported that the DNA alkylator and transcriptional-blocking chemotherapeutic agent trabectedin enhances oncolytic herpes simplex viroimmunotherapy in human sarcoma xenograft models, though the mechanism remained to be elucid…
View article: Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy Open
The use of oncolytic viruses (OVs) and adoptive cell therapies (ACT) have independently emerged as promising approaches for cancer immunotherapy. More recently, the combination of such agents to obtain a synergistic anticancer effect has g…
View article: Supplementary Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs
Supplementary Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs Open
Supplementary Materials and Methods; Figure S1. Western blot of tropomyosin isoforms in neuroblastoma cells used in this project; Figure S2. Effect of combining tropomyosin and microtubule inhibitors on cell growth; Figure S3. A, B, Effect…
View article: Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs
Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs Open
Actin filaments, with their associated tropomyosin polymers, and microtubules are dynamic cytoskeletal systems regulating numerous cell functions. While antimicrotubule drugs are well-established, antiactin drugs have been more elusive. We…
View article: Supplementary Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs
Supplementary Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs Open
Supplementary Materials and Methods; Figure S1. Western blot of tropomyosin isoforms in neuroblastoma cells used in this project; Figure S2. Effect of combining tropomyosin and microtubule inhibitors on cell growth; Figure S3. A, B, Effect…
View article: Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs
Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs Open
Actin filaments, with their associated tropomyosin polymers, and microtubules are dynamic cytoskeletal systems regulating numerous cell functions. While antimicrotubule drugs are well-established, antiactin drugs have been more elusive. We…
View article: Data from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Data from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients Open
Purpose: HSV1716 is an oncolytic herpes simplex virus-1 (HSV-1) studied in adults via injection into the brain and superficial tumors. To determine the safety of administering HSV1716 to pediatric patients with cancer, we conducted a phase…
View article: Data from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Data from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients Open
Purpose: HSV1716 is an oncolytic herpes simplex virus-1 (HSV-1) studied in adults via injection into the brain and superficial tumors. To determine the safety of administering HSV1716 to pediatric patients with cancer, we conducted a phase…
View article: Supplementary Table S1 from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Supplementary Table S1 from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients Open
Supplementary Table S1. Dose administered based on post-injection titers.
View article: Supplementary Table S1 from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Supplementary Table S1 from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients Open
Supplementary Table S1. Dose administered based on post-injection titers.
View article: Supplementary Figure Legend from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i>
Supplementary Figure Legend from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i> Open
Supplementary Figure Legend from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo
View article: Supplementary Figure Legend from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i>
Supplementary Figure Legend from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i> Open
Supplementary Figure Legend from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo
View article: Data from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i>
Data from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i> Open
High levels of expression of the human DEK gene have been correlated with numerous human malignancies. Intracellular DEK functions have been described in vitro and include DNA supercoiling, DNA replication, RNA splicing, and transcription.…
View article: Data from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i>
Data from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i> Open
High levels of expression of the human DEK gene have been correlated with numerous human malignancies. Intracellular DEK functions have been described in vitro and include DNA supercoiling, DNA replication, RNA splicing, and transcription.…
View article: Supplementary Figure 1 from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i>
Supplementary Figure 1 from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i> Open
Supplementary Figure 1 from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo
View article: Supplementary Figure 1 from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i>
Supplementary Figure 1 from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation <i>In vitro</i> and <i>In vivo</i> Open
Supplementary Figure 1 from Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo
View article: Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics Open
T cells redirected to cancer cells either via a chimeric antigen receptor (CAR-T) or a bispecific molecule have been breakthrough technologies; however, CAR-T cells require individualized manufacturing and bispecifics generally require con…
View article: Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma
Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma Open
Osteosarcoma remains one of the deadliest cancers in pediatrics and young adults. We administered two types of immunotherapies, oncolytic virotherapy and immune checkpoint inhibition, to two murine osteosarcoma models and observed divergen…
View article: Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study
Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study Open
Objective Determine if oncolytic herpes simplex virus (oHSV) can eradicate cholesteatoma (CHST) in a gerbil model. Methods An in vivo model of CHST was developed in Mongolian gerbils by combining Pseudomonas aeruginosa inoculation with dou…
View article: Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs
Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs Open
Actin filaments, with their associated tropomyosin polymers, and microtubules are dynamic cytoskeletal systems regulating numerous cell functions. While antimicrotubule drugs are well-established, antiactin drugs have been more elusive. We…
View article: Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients Open
Purpose: HSV1716 is an oncolytic herpes simplex virus-1 (HSV-1) studied in adults via injection into the brain and superficial tumors. To determine the safety of administering HSV1716 to pediatric patients with cancer, we conducted a phase…
View article: Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation Open
Malignant peripheral nerve sheath tumor (MPNST) and neuroblastoma models respond to the investigational small molecule Aurora A kinase inhibitor, alisertib. We previously reported that MPNST and neuroblastomas are also susceptible to oncol…